Early trial for Tough-to-Treat blood cancer halted after two patients
NCT ID NCT06351644
Summary
This early-stage study aimed to test the safety and early effectiveness of a new oral drug, narazaciclib, combined with a steroid (dexamethasone) for adults with multiple myeloma that has returned or stopped responding to multiple prior treatments. The goal was to find a safe dose and see if the combination could help control the cancer. The trial was terminated early after enrolling only two participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mount Sinai Health System
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.